Janux Therapeutics, Inc. Common Stock
JANXJanux Therapeutics, Inc. (JANX) is a biotech company focused on developing innovative treatments that target tumor-associated antigens using its proprietary TRIG™ (Triggered Recruitment of Immune Genes) platform. The company aims to create therapies that harness the body's immune system to fight cancer more effectively.
Company News
Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb worth up to $800 million. Janux will receive $50 million in upfront and near-term milestone payments, with Bristol Myers Squibb handling subsequent development and commercialization of novel immunotherapies for solid tumors. The deal v...
Janux Therapeutics stock rose nearly 12% after an analyst raised his price target, though he maintained a 'sector perform' rating. The company also launched a $300 million secondary stock offering to advance its cancer treatment pipeline.
Throughout the last three months, 9 analysts have evaluated Janux Therapeutics (NASDAQ:JANX), offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months ...
In the preceding three months, 9 analysts have released ratings for Janux Therapeutics (NASDAQ:JANX), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish...
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -0.43% and 5.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
